Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

OBJECTIVE: To evaluate apremilast treatment in patients with active psoriatic arthritis, including current skin involvement, despite prior therapy with conventional disease-modifying antirheumatic drugs and/or biologic agents. METHODS: Patients (N=505) were randomised (1:1:1) to placebo, apremilast...

Descripción completa

Detalles Bibliográficos
Autores principales: Edwards, Christopher J, Blanco, Francisco J, Crowley, Jeffrey, Birbara, Charles A, Jaworski, Janusz, Aelion, Jacob, Stevens, Randall M, Vessey, Adele, Zhan, Xiaojiang, Bird, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893110/
https://www.ncbi.nlm.nih.gov/pubmed/26792812
http://dx.doi.org/10.1136/annrheumdis-2015-207963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4893110/
https://www.ncbi.nlm.nih.gov/pubmed/26792812
http://dx.doi.org/10.1136/annrheumdis-2015-207963

Ejemplares similares